Program
Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934
Also written as “TQB2934 injection” and “TQB2934 injection (subcutaneous injection)”.
In Sino Biopharmaceutical’s pipeline, BCMA/CD3双抗
. Its studies are mostly in Multiple Myeloma · Amyloidosis, led by Sino Biopharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 44 open or running | phase 3since Apr 29, 2026 | Dec 1, 2022 | Oct 2027phase 1 · NCT07179679 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 1, 2022First study: phase 1 study in Multiple MyelomaFirst studyNCT05646758 · 140 planned · China
- Sep 9, 2025Phase 1 study in Multiple MyelomaNCT07179679 · 42 planned · China
- Nov 25, 2025Phase 2 study in Systemic Light Chain AmyloidosisNCT07266116 · 70 planned · China
- Apr 29, 2026Phase 3 study in Multiple MyelomaPhase 3 reachedNCT07569757 · 260 planned · China
Ahead
- Oct 2027Primary completion: phase 1 study in Multiple MyelomaNCT07179679
- Dec 2028Primary completion: phase 3 study in Multiple MyelomaNCT07569757
- Feb 2029Primary completion: phase 2 study in Systemic Light Chain AmyloidosisNCT07266116
TargetBeta
“BCMA/CD3双抗”the company's pipeline, read by Claude · source
“A T-cell engaging, human, bispecific, immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and CD3 antigen found on T-lymphocytes, ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| elranatamabrule | Pfizer | phase 4 | 15 |
| linvoseltamabrule | Regeneron Pharmaceuticals | phase 4 | 13 |
| teclistamabrule | Johnson & Johnson | phase 4 | 11 |
| etentamig | AbbVie | phase 3 | 11 |
| ramantamig | Johnson & Johnson | phase 3 | 8 |
| GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003rule | Innovent Biologics | phase 3 | 4 |
| cizutamigrule | UCB | phase 2 | 5 |
| vonsetamigrule | Regeneron Pharmaceuticals | phase 2 | 3 |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 2 |
| LVV Expressing VSV Glycoprotein/Anti-CD3 scFv Containing Transgene Encoding for Anti-BCMA CAR KLN-1010rule | kelonia-therapeutics-inc | phase 1 | 1 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07569757Multiple Myeloma · China | 3 | Not yet recruiting | Dec 2028 | 260 |
| NCT07266116Systemic Light Chain Amyloidosis · China | 2 | Recruiting | Feb 2029 | 70 |
| NCT07179679Multiple Myeloma · China | 1 | Recruiting | Oct 2027 | 42 |
| NCT05646758Multiple Myeloma · China | 1 | Recruiting | Oct 2024 | 140 |
How it is read
Names in the registry
- “TQB2934 injection”, 3 entries
- “TQB2934 injection (subcutaneous injection)”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 3 studies
- Amyloidosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.